Top Page
SSY Group
(OTC:2005)
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
SSY Group Business Overview & Revenue Model
SSY Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.77B | 6.46B | 6.43B | 5.36B | 4.26B |
| Gross Profit | 2.91B | 3.62B | 3.44B | 3.04B | 2.58B |
| EBITDA | 1.74B | 2.11B | 1.86B | 1.40B | 1.09B |
| Net Income | 1.06B | 1.32B | 1.12B | 785.53M | 611.97M |
Balance Sheet | |||||
| Total Assets | 12.60B | 11.97B | 10.97B | 10.71B | 9.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.62B | 1.76B | 1.73B | 1.51B |
| Total Debt | 3.64B | 3.37B | 3.21B | 3.11B | 2.44B |
| Total Liabilities | 5.07B | 4.70B | 4.26B | 4.11B | 3.24B |
| Stockholders Equity | 7.22B | 6.93B | 6.21B | 6.22B | 5.65B |
Cash Flow | |||||
| Free Cash Flow | -49.39M | 221.88M | 368.70M | 359.58M | 236.61M |
| Operating Cash Flow | 491.03M | 925.75M | 786.82M | 747.91M | 527.64M |
| Investing Cash Flow | -521.76M | -640.19M | -412.77M | -681.23M | -287.58M |
| Financing Cash Flow | -295.42M | -304.57M | -219.30M | 136.13M | 318.57M |
SSY Group Technical Analysis
SSY Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $8.88B | 8.68 | 14.96% | 6.31% | -10.67% | -19.27% | |
69 Neutral | €3.43B | 23.91 | 22.76% | 2.44% | 32.58% | 18.20% | |
| ― | $1.62B | ― | -4.93% | 2.69% | ― | ― | |
| ― | €1.07B | 8.15 | 23.28% | 6.13% | ― | ― | |
74 Outperform | HK$6.25B | 6.93 | 11.61% | 9.30% | -18.09% | -15.08% | |
73 Outperform | HK$1.95B | 3.19 | 18.33% | 4.65% | -9.95% | 67.56% | |
70 Outperform | HK$11.23B | 12.92 | 8.89% | 3.02% | 4.91% | -11.80% |
SSY Group Corporate Events
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new drugs: Ketotifen Fumarate Eye Drops and Calcium Gluconate Injection. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by expanding its portfolio of ophthalmic and treatment drugs.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Cupric Chloride has received approval from the National Medical Products Administration of China for market preparations. This approval marks the third of its kind for PRC entities, indicating a significant step in the company’s product development and potential market expansion, enhancing its position in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of Potassium Chloride and Sodium Chloride Injection. This development marks the second such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by meeting consistency evaluation standards. The injections are used for treating hypokalemia and heart issues caused by digitalis poisoning, potentially impacting the company’s operations positively by expanding its product offerings.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced significant progress in its innovative drug development projects. The company’s SYN045 tablets, designed to treat pulmonary hypertension, have shown promising results in Phase I clinical trials, with improvements in safety and tolerability. The company plans to advance to Phase IIa trials to further explore efficacy and safety. Additionally, SSY Group is developing new drugs targeting epilepsy and pain treatment, with ongoing compound screening and toxicity assessments. The company is committed to accelerating its drug development efforts and keeping stakeholders informed of its progress.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Paracetamol Granules, a type 3 chemical drug specifically designed for children. This approval grants the company exclusive rights among PRC entities to produce this medication, which is used to treat fever and mild to moderate pain in children, potentially enhancing its market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Furosemide Tablets (20mg), a type 3 chemical drug. This development is significant for the company as it enhances their product portfolio in treating conditions such as edema, hypertension, and acute kidney failure, potentially strengthening their market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two drugs: Diprophylline Injection and Formoterol Fumarate Inhalation Solution. These approvals enhance the company’s portfolio in respiratory treatments, potentially strengthening its market position and offering new options for patients with conditions like asthma and COPD.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group has established a Nomination Committee to oversee the appointment of directors, ensuring fair and transparent nominations in line with corporate governance standards. The committee, which includes independent non-executive directors, is tasked with reviewing board composition, assessing director independence, and managing succession planning, thereby strengthening the company’s governance framework.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced the appointment of Ms. Qu Wanrong as a member of its Nomination Committee, effective June 20, 2025. Ms. Qu, who has been with the company since 2014 and serves as an executive director and deputy general manager, brings extensive experience in financial audit, public relations, and corporate communications. Her appointment aligns with the company’s compliance with the amended Corporate Governance Code and Listing Rules, enhancing its governance structure and promoting gender diversity within the committee.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced the composition of its board of directors and the roles within its board committees, effective from June 20, 2025. This announcement is significant as it outlines the leadership structure and governance, which could impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its caffeine product has received the Certificate of Suitability to the European Pharmacopoeia monograph (CEP) from the European Directorate for the Quality of Medicines and HealthCare. This certification is expected to enhance the company’s international sales, brand image, and market share, particularly in European and American markets, by meeting high production and quality standards.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new chemical drugs: Tranexamic Acid and Sodium Chloride Injection, and Levocarnitine Oral Solution. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by addressing bleeding disorders and carnitine deficiency.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Timolol Maleate Eye Drops in unit dose packaging. This marks the company’s first approval of this kind in China and is part of its strategy to expand its ophthalmic product line. The new product is designed to effectively reduce intraocular pressure in various types of glaucoma, enhancing SSY Group’s position in the pharmaceutical market and potentially opening new sales channels by the end of the year.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two chemical drugs: Calcium Gluconate and Sodium Chloride Injection, and Potassium Chloride Granules. These approvals mark a significant step in the company’s product development, enhancing its portfolio in treating conditions such as acute hypocalcemia and hypokalemia, which could strengthen its market position and offer new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited announced a significant decline in its unaudited operating results for the first quarter of 2025, with a 36.9% decrease in turnover compared to the same period in 2024. The drop in sales volume of intravenous infusion solutions and ampoule injections contributed to a 50.6% decrease in gross profit and a 59.5% decrease in profit attributable to shareholders. This downturn in financial performance could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two drugs: Dronedarone Hydrochloride Tablets and Gabexate Mesylate for Injection. These approvals mark significant advancements in the company’s product offerings, with Dronedarone Hydrochloride targeting atrial fibrillation and Gabexate Mesylate addressing acute pancreatitis. This development enhances SSY Group’s position in the pharmaceutical market, potentially benefiting stakeholders by expanding the company’s portfolio and market reach.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited held its Annual General Meeting (AGM) in 2025, where all proposed resolutions were passed. Key decisions included the re-election of executive directors, the re-appointment of KPMG as the auditor, and the approval of a final dividend. The meeting also granted the board of directors mandates to issue and repurchase shares, reflecting strong shareholder support and potentially impacting the company’s future financial strategies.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its drug Riluzole has received approval from the National Medical Products Administration of China for market use as a bulk drug. This development is significant as Riluzole is used to extend the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. The approval marks a crucial step in SSY Group’s product development, potentially enhancing its market position and offering new treatment options for ALS patients.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its product, Lornoxicam, has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the pharmaceutical industry by expanding its portfolio of pain management solutions.
SSY Group Limited has announced that its product, Allopurinol, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, particularly in the treatment of gout and high uric acid, potentially enhancing its position in the pharmaceutical market.
SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of new pharmaceutical products, including Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets and Ibuprofen Arginine Granules. These developments are expected to enhance the company’s product offerings in diabetes management and pain relief. Additionally, the company has obtained registration approvals for Acipimox and Diprophylline as bulk drugs, which will support their market presence in treating hyperlipidemia and respiratory conditions.